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Abstract 
A 29-year-old man with advanced hilar cholangiocarcinoma was successfully treated with 
an extended right lobectomy. The carbohydrate antigen 19-9 (CA19-9) level was elevated 
to 939 IU/l, and the pathological findings revealed moderately differentiated tubular 
adenocarcinoma which involved almost the entire thickness of the hepatic duct and the 
adjacent liver tissue (T3) and which was associated with lymph node metastasis (N1). It 
was a stage IIB (T3N1M0) tubular adenocarcinoma according to UICC pathological 
staging. Immunohistochemical examination revealed that Ki-67, cyclin D1, and MMP-7 
were positive, and 14-3-3σ and p27 were negative. The pathological and immunohisto-
chemical findings indicated high malignant potential indicating poor prognosis. We 
administrated the postoperative adjunct gemcitabine combined with S-1 chemotherapy. 
The patient is alive without recurrence and doing well two years after surgery. We also 
review other reports of cholangiocarcinoma patients aged less than 30 years. 
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Introduction 
Hilar cholangiocarcinoma (HC) is a rare tumor characterized by slow growth; the 
average patient age at clinical diagnosis of HC is 60–79 years, and HC in patients aged less 
than 30 years has not been reported in Japan [1]. Despite the reputed slow tumor growth 
rate and uncommon hematogenous metastasis, the propensity for extensive local invasion 
of the hepatic hilum and the limited resolution of hepatic hilar imaging initially 
accounted for low overall resectability [2]. Complete resection remains the only therapy 
that offers the possibility of long-term survival, and hepatic resection is a critical 
component of the surgical approach. 
Several reports have described the prognostic factors for cholangiocarcinoma [2–9], 
which include operative resectability [3–6], portal vein invasion [7], lymph node 
metastasis [8], and age [9]. In this paper, we report a case of a resected advanced HC 
arising in a 29-year-old male without primary sclerosing cholangitis (PSC) with an 
immunohistochemical examination of prognostic factors and review other reports of 
cholangiocarcinoma patients aged less than 30 years. 
Case Report 
A 29-year-old man presented with cholecystolithiasis was admitted to our hospital; his condition was 
detected by ultrasonography. Physical examination revealed no palpable mass in the abdomen. His 
laboratory findings upon admission are shown in table 1. Although the serum carcinoembryonic 
antigen (CEA) level was within the normal range, the carbohydrate antigen 19-9 (CA19-9) level was 
elevated to 939 IU/l. 
Abdominal ultrasonography and abdominal computed tomography revealed a hypovascular mass 
measuring 2.5 cm at the hilum and dilation of the intrahepatic bile duct of the right lobe (fig. 1a). An 
endoscopic retrograde cholangiopancreatography (ERCP) showed complete obstruction of the right 
hepatic duct and narrowing of the common hepatic duct (fig. 1b). A fluorodeoxyglucose (FDG) positron 
emission tomographic scan revealed a high FDG uptake with a maximal standardized uptake value of 
5.8 (fig. 1c). A HC was suspected based on these findings. We recommended surgery and performed an 
extended right lobectomy with bile duct resection. The tumor had invaded to the right branch of the 
portal vein and the right lobe was atrophic at operation (fig. 1d). The operation time was 7 h and 
25 min. Blood loss was 425 ml and no blood transfusion was administered. The resected specimen was a 
tumor 2.5 cm in diameter and involving the right hepatic duct and right portal vein (fig. 1e). 
The pathological findings revealed a moderately differentiated tubular adenocarcinoma, which 
involved almost the entire thickness of the hepatic duct and the adjacent liver tissue (T3) and which was 
associated with lymph node (N1) metastasis. It was a stage IIB (T3N1M0) tubular adenocarcinoma 
according to UICC pathological staging. 
The sections were examined immunohistochemically with primary antibodies using the streptavidin 
peroxidase complex method. The antibodies and the immunohistochemical results are summarized in 
table 2 and figure 2. Ki-67 [10] and cyclin D1 [11] were stained cancer cell nuclei, and the labeling 
indices were 24 and 30.4%, respectively (fig. 2b, c). MMP-7 [12] densely stained the cytoplasm of almost 
all cancer cells (fig. 2d), whereas 14-3-3σ [13] and p27 [14] staining were negative. 
The pathological and immunohistochemical findings revealed that this tumor exhibited a high 
malignant potential, indicating poor prognosis. We administrated the postoperative adjunct 
gemcitabine (GEM) combined with S-1 chemotherapy on postoperative day 37. We orally administrated 
40 mg S-1 twice daily for seven days followed by a 1-week blank. We administrated 1,000 mg GEM in a 
1-hour intravenous infusion on day 1, and this cycle was repeated every 14 days. The patient is alive 
without recurrence and doing well two years after surgery.  
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Discussion 
Because of the lack of early symptoms, most patients are diagnosed with HC at an 
advanced stage, by which it is found that the cancer has often metastasized or invaded the 
adjacent liver, portal vein, or hepatic artery. Despite a reputed slow tumor growth rate 
and uncommon hematogenous metastasis, the propensity for extensive local invasion of 
the hepatic hilum and the limited resolution of hepatic hilar imaging initially accounted 
for the low overall resectability. As a consequence of limited resectability of HC, the 
prognosis is poor, and surgical management is primarily palliative. Rea et al. reported 
on patients with HC undergoing hepatic and biliary tract resection and regional 
lymphadenectomy with Roux-en-Y hepaticojejunostomy. The actual 5-year survival rate 
of patients was 26%, and the few clinicopathological factors were associated with survival 
[2]. 
A right hepatectomy most likely enables the en bloc resection of the hepatic ductal 
confluence and its surrounding structures because the confluence lies on the right side of 
the hepatic hilum. Kondo et al. analyzed tumor recurrence after R0 resections and 
indicated a low frequency of local recurrence and a high frequency of peritoneal seeding, 
contrary to previous reports describing locoregional recurrence as the most common 
mode [5]. Hasegawa et al. also described that surgery is the only potentially curative 
treatment for hilar bile duct cancer [6]. Aggressive surgical approaches including radical 
hepatectomy based on the precise knowledge of the surgical anatomy of the hepatic hilum 
and meticulous surgical technique can achieve a 77% R0 rate and a relatively low rate of 
local recurrence. They identified lymph node metastases as another independent 
prognostic factor. Kondo et al. reported a high R0 rate (95%) in 40 major hepatectomy 
cases with a low local recurrence rate [5]. In contrast, Hasegawa et al. reported that more 
than half (60%) of the patients with R0 operations developed distant metastases [6]. These 
results indicated the limitation of the surgeries, which are able to achieve only local 
control of the tumor.  
Portal vein invasion was previously a main cause for HC unresectability. Ebata et al. 
performed combined hepatobiliary and portal vein resection in patients with advanced 
HC and concluded that adjuvant therapy is important because of the modest 
improvement in survival following portal vein resection [7]. Furthermore, it was also 
reported that R0 resection remains the best treatment for ensuring long-term survival, 
and lymph node status is the most important prognostic factor following R0 resection [8]. 
Several authors have reported cholangiocarcinomas in patients aged less than 39 years 
(table 3) [9, 15–17]. Yeh et al. indicated that age is a risk factor for cholangiocarcinoma 
and that only one patient in the younger cholangiocarcinoma group survived for 
24.2 months, whereas the remaining patients died within 12 months [9]. Bjornsson and 
Angulo reported eight cases of cholangiocarcinoma with PSC and five without PSC [17]. 
Although three of eight cholangiocarcinoma patients with PSC were alive for 7 months 
to 7 years, all cholangiocarcinoma patients without PSC died within 18 months. 
Cholangiocarcinoma in younger patients had reached a highly advanced stage and these 
patients showed a lower incidence of operation than older cholangiocarcinoma patients. 
Clinicopathologically, our case may have had a poor prognosis because of age, portal 
vein invasion, and lymph node metastasis. In this report, we immunohistochemically 
examined the cell-regulating factors (cyclin D1, Ki-67, 14-3-3σ, and p27), growth factors 
(c-erbB2 and EGFR), and MMPs (MMP-2 and MMP-7). We found that this patient not 
only showed Ki-67 [10], cyclin D1 [11] and MMP-7 [12] overexpression, but also  
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decreased 14-3-3σ [13] and p27 [14] expression. These findings demonstrated that the 
cancer exhibited a high proliferative and invasive activity. 
From the pathological findings, we concluded an R0 operation in our case; however, 
portal vein invasion and lymph node metastasis were also present. Additional treatment 
modalities such as systemic adjuvant chemotherapy must be developed to control 
systemic cancer cell micrometastasis for improving the survival of patients with HC. 
Results of a recent phase II study revealed that GEM [18, 19] and S-1 [20] therapies are 
effective for cholangiocarcinoma. Furthermore, a combination therapy with GEM and S-1 
was well tolerated and yielded a significantly high response rate in metastatic [21] and 
resected [22] pancreatic cancers. Our patient received adjuvant GEM combined with S-1 
therapy, showing no side effects and good drug tolerance. There was no evidence of 
tumor recurrence two years after surgery. He is doing well and is employed. 
In conclusion, we reported a 29-year-old male patient who underwent a major 
hepatectomy for advanced HC. He is alive without any recurrence and doing well two 
years after surgery. We conclude that an R0 operation and adjuvant chemotherapy could 
be an effective treatment strategy for advanced HC. 
 
 
 
Table 1. Laboratory findings in the present case 
Peripheral blood counts  Biochemistry 
RBC, ×10
4  0.458 TP,  g/dl  .7.1 
Hb, g/dl  014.4 Alb,  g/dl  .3.8 
Ht, %  041.6 T-Bil,  g/dl  .0.6 
Plt, ×10
4  019.4 AST,  IU/l  033 
WBC 4,740  ALT,  IU/l  054 
Coagulation   ALP,  IU/l  166 
PT, %  0.104 g-GTP,  IU/l  209 
APTT, s  035.2 FBS,  mg/dl  090 
Immunology   BUN,  mg/dl  .6.5 
CRP, mg/dl  000.3 Cr,  mg/dl  .0.8 
Tumor markers    Na, mEq/l  139 
CEA, ng/ml  002.1 K,  mEq/l  .4.1 
CA19-9, U/ml  0.939 Cl,  mEq/l  101 
 
 
Table 2. Immunohistochemical examination of the resected specimen 
Antigen  <Positivity Prognosis  Reference 
Ki-67  <30.4% poor  10 
p53  0<0%    
14-3-3σ  0<0% poor  13 
Cyclin D1  <24% poor  11 
c-erbB2  <negative    
EGFR  <negative    
p27 <10%  poor  14 
MMP-2  <negative    
MMP-7 >90%  poor 12 
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Table 3. Cases with cholangiocarcinoma under 30 years old 
Authors Country  n  Age  PSC  Reference 
Kitagawa et al.  Japan  1  24  ?  15 
Yeh et al.  Taiwan  1  28  ?  09 
Klein et al.  USA  1  25  –  16 
Bjornsson and Angulo  USA  5  21–25  –  17 
Present report  Japan  1  29  –  0– 
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Fig. 1. Imaging and operative findings. a A computed tomography scan demonstrated hypovascular 
masses (arrows) at the hilum and slight dilation of the intrahepatic bile duct of the right lobe. b An 
ERCP showed complete obstruction of the right hepatic duct and narrowing of the common hepatic 
duct (arrow). c A FDG positron emission tomographic scan; the mass showed high FDG uptake with a 
maximal standardized uptake value of 5.8. d Operative findings. The tumor invasion into the right 
branch of the portal vein (arrows). e A resected specimen. The tumor was 2.5 cm in diameter and 
involved the right hepatic duct (HD) and right portal vein (PV). 
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Fig. 2. Pathological and immunohistochemical findings of the resected specimen. a Hematoxylin and 
eosin staining revealing a moderately differentiated tubular adenocarcinoma. b Ki-67 staining of cancer 
cell nuclei; the labeling index was 24%. c Cyclin D1 staining of cancer cell nuclei; the labeling index was 
30.4%. d Dense MMP-7 staining of the cytoplasm of almost all cancer cells. 
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